Jarosinski, M., Lowenkamp, M., Madigan, M., Reitz, K., Chaer, R., Sridharan, N. (2025). Abstract 4367010: Dual Pathway Inhibition prescription after percutaneous vascular intervention is low, and dependent on physician and treating facility practice patterns. Circulation. https://doi.org/10.1161/circ.152.suppl_3.4367010